Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2015
For the year, the company reported contract revenue of $3,111,000 compared to $9,631,000 a year ago. Loss from operations was $2,626,000 compared to $80,000 a year ago. Net loss was $2,628,000 or $0.02 per basic and diluted share compared to $80,000 or $0.00 per basic and diluted share a year ago. Diluted net loss attributable to common stockholders was $2,628,000 compared to $80,000 a year ago. Net cash used in operating activities was $2,443,000 compared to net cash provided by operating activities of $323,000 a year ago.